Company intelligence / Profile preview

Neurovascular Diagnostics

Buffalo, New York, United States

Ownership: Private
Employees: ~25
Development stage: Other

Overview

Neurovascular Diagnostics is developing AneuScreen, a blood-based, non-invasive test to prescreen and risk stratify patients for unruptured brain aneurysms. Early research shows the test can correlate blood biomarkers (notably neutrophil gene expression) with aneurysm presence and size. The company is finalizing the biomarker panel and testing it in multisite clinical cohorts supported by NIH and NSF funding[2].

Therapeutic areas: Neurology
Modalities: DeviceDiagnostic assay
Industry: Molecular Diagnostics

Partnerships

National Institutes of Health (NIH) SBIR program[2]National Science Foundation (NSF)[2]University at Buffalo Center for Advanced Technology in Big Data and Health Sciences[2]

Beyond the preview

Go deeper on Neurovascular Diagnostics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Neurovascular Diagnostics.

Explore the full profile